These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
537 related items for PubMed ID: 23201006
1. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Tang L, Han X. Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006 [Abstract] [Full Text] [Related]
2. Urokinase-type plasminogen activator system and breast cancer (Review). Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776 [Abstract] [Full Text] [Related]
3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R, Schaaf A. Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [Abstract] [Full Text] [Related]
4. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K. Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628 [Abstract] [Full Text] [Related]
6. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Duffy MJ, Duggan C. Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235 [Abstract] [Full Text] [Related]
7. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S. Cancer Res; 2007 Jan 01; 67(1):9-15. PubMed ID: 17210677 [Abstract] [Full Text] [Related]
10. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Stillfried GE, Saunders DN, Ranson M. Breast Cancer Res; 2007 Jan 01; 9(1):R14. PubMed ID: 17257442 [Abstract] [Full Text] [Related]
11. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104 [Abstract] [Full Text] [Related]
17. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647 [Abstract] [Full Text] [Related]
18. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T. Scand J Gastroenterol; 2005 Jul 01; 40(7):783-93. PubMed ID: 16109653 [Abstract] [Full Text] [Related]
19. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Jankun J, Merrick HW, Goldblatt PJ. J Cell Biochem; 1993 Oct 01; 53(2):135-44. PubMed ID: 8227186 [Abstract] [Full Text] [Related]